Marathon Asset Management (UK)’s Royalty Pharma RPRX Stock Holding History

Marathon Asset Management (UK)’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16M	Sell	285,951 -154,977	-35%	-$8.07M	0.65%	43
2026 Q1	$21.2M	Buy	440,928 +52,702	+14%	+$2.31M	0.81%	41
2025 Q4	$15M	Sell	388,226 -37,846	-9%	-$1.44M	0.58%	48
2025 Q3	$15M	Sell	426,072 -153,549	-26%	-$5.56M	0.55%	46
2025 Q2	$20.9M	Sell	579,621 -66,625	-10%	-$2.21M	0.67%	45
2025 Q1	$20.1M	Sell	646,246 -68,924	-10%	-$2.18M	0.61%	46
2024 Q4	$18.2M	Sell	715,170 -46,981	-6%	-$1.25M	0.51%	53
2024 Q3	$21.6M	Buy	762,151 +18,424	+2%	+$510K	0.6%	51
2024 Q2	$19.6M	Sell	743,727 -48,680	-6%	-$1.35M	0.61%	55
2024 Q1	$24.1M	Sell	792,407 -60,011	-7%	-$1.77M	0.64%	55
2023 Q4	$23.9M	Buy	852,418 +86,585	+11%	+$2.38M	0.67%	58
2023 Q3	$20.8M	Sell	765,833 -37,334	-5%	-$1.11M	0.65%	59
2023 Q2	$24.7M	Sell	803,167 -90,025	-10%	-$3.05M	0.69%	56
2023 Q1	$32.2M	Sell	893,192 -138,077	-13%	-$5.12M	0.9%	46
2022 Q4	$40.8M	Sell	1,031,269 -42,476	-4%	-$1.77M	1.1%	33
2022 Q3	$43.1M	Sell	1,073,745 -891,591	-45%	-$38.1M	1.29%	30
2022 Q2	$82.6M	Sell	1,965,336 -111,392	-5%	-$4.57M	1.38%	24
2022 Q1	$80.9M	Sell	2,076,728 -165,602	-7%	-$6.5M	1.1%	39
2021 Q4	$89.4M	Buy	+2,242,330	New	+$87.1M	1.11%	39

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marathon Asset Management (UK)'s RPRX Position: Q2 2026 in Review

Marathon Asset Management (UK) reduced its Royalty Pharma (RPRX) stake by 35% in Q2 2026, selling an estimated $8.07M and leaving 285,951 shares worth $16M. The position accounts for 0.65% of the portfolio, ranked #43.

Marathon Asset Management (UK) first reported a position in RPRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $89.4M in Q4 2021. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Marathon Asset Management (UK) held 285,951 shares of Royalty Pharma worth $16M as of Q2 2026.
Marathon Asset Management (UK) sold 154,977 Royalty Pharma shares in Q2 2026, an estimated $8.07M.
Royalty Pharma made up 0.65% of Marathon Asset Management (UK)'s portfolio in Q2 2026, its #43 holding.
Marathon Asset Management (UK) first reported a position in Royalty Pharma in Q4 2021 and has held it in 19 quarters since.
Marathon Asset Management (UK)'s Royalty Pharma position peaked at $89.4M in Q4 2021.
647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Marathon Asset Management (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.